Program

Break

SUNDAY, DECEMBER 3, 2017

OPENING SESSION
 15:00

Opening Remarks: Science Drives Success
Raymond F Schinazi
Emory University

INVESTING IN A CURE: No One Creates Success Alone
Chairs: Ana Lok, Michigan University, USA - Hélène Strick-Marchand, Pasteur, France
 15:10Plenary Presentation
Eliminating Hepatitis C by 2030 -  Enhancing Prevention Care and Treatment Among People who Inject Drugs
Margaret Hellard
Monash University, Australia
 15:50Strategy for the Elimination of Hepatitis B and C (Academy of Medicine Report)
Andrew Aronsohn
University of Chicago, USA
 16:10Elimination of HCV: The DC Story
Henry Masur
NIH, USA
 16:30The French and European Approach Towards Hepatitis Elimination
Tarik Asselah
Hôpital Beaujon, France
 16:50Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition
Ana Lok
Michigan University, USA
 17:10Global Strategies to Eliminate Hepatitis B (ICE-HBV)
Peter Revill
Victorian Infectious Diseases Reference Laboratory, Australia
 
ORAL ABSTRACT SESSION I
 17:20

Epidemiologic impact of expanding chronic hepatitis C (CHC) treatment in people who inject drugs (PWID) in the United States (US): a mathematical model using data from the C-EDGE CO-STAR Study
Michael Robertson, Merck, USA

 17:40

Novel Nucleosides, CMCP and CFCP, Potently Block the Infectivity and Replication of Wild-type and Drug-resistant HBVs in Culture and in Human-liver-chimeric Mice and Show Potential QW or Q2W (64)
Hiroaki Mitsuya, National Institutes of Health, USA

 
17:50Welcome Reception
 

MONDAY, DECEMBER 4, 2017

DISCOVERIES AND ADVANCES IN HEPATITIS RESEARCH
Chairs: Francis Chisari; The Scripps Research Institute, USA - Harvey Alter; National Institutes of Health, USA
 8:00Introduction and Presentation of the William H. Prusoff HEP DART Lifetime Achievement Award
Raymond F. Schinazi
Emory University
 8:10Introduction by Joan Block
 8:20William H. Prusoff HEP DART Lifetime Achievement Award Lecture:
Access to HIV, HBV, and HCV Antiviral Agents Globally 

John Martin
Gilead Sciences, USA
 
PROSPECTS FOR A CURE
Chairs: Jake Liang, National Institutes of Health, USA - Jeffrey Glenn, Stanford University, USA
 9:00Plenary Presentation
Liver Disease in Chinese-perspective from a Hepatologist
George Lau
Humanity & Health Medical Group, Hong Kong
 9:40DAA Therapy and Reinfection Among People who Inject Drugs: Forming a Foundation for HCV Elimination
Jason Grebely
University of New South Wales, Australia
10:00Break
 10:30Short Duration DAA HCV Therapy: How Short Can We Go?
Shyamasundaran Kottilil
University of Maryland, USA
 10:50A Tale of Two Viruses: HBV and HCV Co-Infection
Jake Liang
NIH, USA
 11:10The Global Burden of Non-Alcoholic Steatohepatitis
Zobair Younossi
Inova Health System, USA
 11:30Special Lecture
Hepatitis B/C and NASH: Crossroads Between Science and Business

Geoffrey Meacham
Barclays Biotech/Pharma Research, USA
12:00Panel Discussion
 
ORAL ABSTRACT SESSION II
12:20

Elucidating the structural and dynamic mechanism of resistance for clinically relevant variants against HCV NS3/4A protease inhibitors
Ashley Matthew; University Of Massachusetts Medical School, USA

 12:30

Real-world utilization and effectiveness of elbasvir/grazoprevir in adult patients with chronic hepatitis C in Canada: Z-PROFILE study
Edward Tam; Merck Canada Inc., Canada

12:40Lunch
 
HEPATITIS B VIRUS: BASIC SCIENCE
Chairs: Fabien Zoulim, University of Lyon, France - Stephen Locarnini; Victorian Infectious Diseases Reference Laboratory, Australia
 15:30Plenary Presentation
Catch Me If You Can – Tuning Immunity for HBV Cure

Ulrike Protzer
Technical University of Munich, Germany
 16:10Immunology of HBV
Adam Gehring
Toronto Centre for Liver Disease, Canada
 16:30Optimizing Infection Systems and Screens and Studying Innate anti-HBV Factors and Mechanisms
Lefteris Michailidis
Rockefeller University, USA
 
16:50Break
 
THE PATH AHEAD: HEPATITIS B RESERVOIRS, CONTROL AND ELIMINATION
Moderators: Mark Sulkowski; The Johns Hopkins University, USA - Raymond F. Schinazi; Emory University, USA
 17:20Special Lecture
Personalized Approaches to HBV Cure

Marion Peters
University of California, USA
 Debate: Is Host Genome Integrated HBV Relevant?
 17:50The Con Perspective
Stephen Locarnini
Victorian Infectious Diseases Reference Laboratory, Australia
 18:10The Pro Perspective
Christian Brechot
Global Virus Network, USA
 18:30Panel Discussion
 
19:20Adjourn
 

TUESDAY, DECEMBER 5, 2017

TARGETS, MODELS, THERAPIES AND CURES FOR HEPATITIS VIRUS
Chairs: Eugene Schiff, University of Miami, USA - Ulrike Protzer; Technical University of Munich, Germany
8:00Plenary Presentation
Endpoints and New Targets for Curing Hepatitis B
Stephen Locarnini
Victorian Infectious Diseases Reference Laboratory, Australia
8:40Targeting the HBV-Macrophage-Stellate cell axis to treat HBV-induced Liver Diseases
Lishan Su
University of North Carolina at Chapel Hill, USA
9:00Core Antibody: anti-HBc What is the Core of the Story?
Robert Gish
Hepatitis B Foundation, USA
9:20Development of Immune Competent Small Animal Models for HBV
Hélène Strick-Marchand
Pasteur Institute, France
9:40Panel Discussion
 
ORAL ABSTRACT SESSION III
 10:00

In vivo evaluation of anti-HBV CRISPR/Cas9 Therapy in the FRG mouse
Keith Jerome; Fred Hutchinson Cancer Research Center, USA

 10:10

A Novel Immunotherapy for Chronic HBV and HDV Infections that Bypass Tolerance and Induce Broadly Crossreactive and Neutralizing Antibodies
Matti Sallberg; Karolinska Institutet, Sweden

 
10:20Break
 

RESISTANCE, CELL BIOLOGY AND OTHER HEPATITIS VIRUSES
Chairs: Tarik Asselah; Hôpital Beaujon, France -
Paul Pockros, Scripps Translational Science Institute, USA

10:40Plenary Presentation
Revisiting the Molecular and Cell Biology of the Hepatitis B Virus Towards Elimination
Fabien Zoulim
University of Lyon, France
 11:20Distinct cellular entry pathways for quasi-enveloped and naked hepatitis A virions 
Stanley Lemon
University of North Carolina at Chapel Hill, USA
 11:40Emerging Therapeutic Targets and Concepts for Delta Hepatitis Virus
Jeffrey Glenn
Stanford University, USA
 12:00HEV Update: Diagnostics and Management
Kenneth Sherman
University of Cincinnati, USA
 12:20Panel Discussion
 
12:30Lunch
 

LOOMING CHALLENGES AND QUESTIONS IN HBV CURE
HEPATITIS B FOUNDATION SESSION:
Chairs: Marion Peters, University of California, San Francisco - Timothy Block; Hepatitis B Foundation, USA

 A Round Table Discussion - Looming Challenges and Questions in the Cure for Chronic Hepatitis B
  
 13:30Introduction
 13:35Is There a Best Direct Acting Antiviral in Development?
Fabien Zoulim; University of Lyon, France
 13:47Is There a Best Host Acting Antiviral in Development?
Jake Liang; National Institutes of Health, USA 
 13:59Is There a Best Immunomodulator in Development?
Ulrike Protzer; Technical University of Munich, Germany
 14:10Discussion by Panel and Audience
 14:30Closing Remarks
 
EVENING SESSION
 15:30Poster Session
 17:00Review of Poster Presentations
Adrian Ray; Gilead Sciences, USA
Harvey Alter; National Institutes of Health, USA
 
SHIFTING TIDE OF DRUG DEVELOPMENT TOWARDS HBV, NASH, AND HCC: BATTLING GIANT KILLERS
Chairs: Kenneth Sherman; University of Cincinnati, USA - Stanley Lemon; University of North Carolina at Chapel Hill, USA
 17:50New directions towards functional cure of Chronic Hepatitis B
Lawrence Blatt
Janssen, USA
 18:10Looking back to move forward: designing next-gen RNAi for best results in HBV
Bruce Given
Arrowhead Pharmaceuticals, USA
 18:30SB 9200: A novel RIG-I agonist for chronic hepatitis B 
Stephen Locarnini
Victorian Infectious Diseases Reference Laboratory, Australia
 18:50Controlling HBsAg as a Key Component of a Combination Strategy to Affect an HBV Cure 
Michael Sofia
Arbutus Biopharma, USA
 19:10Immunotherapy is coming for HCC 
Spiros Hiotis
Mount Sinai Hospital, New York, USA.
 19:30Studies of the HBV-immune modulator AIC649
Helga Rübsamen-Schaeff
AiCuris, Germany
 
 
19:50Adjourn
 

WEDNESDAY, DECEMBER 6, 2017

HEPATITIS C VIRUS – Part 1: THE BAR HAS BEEN RAISED TO 98% SVR
Chair: George Lau; Humanity and Health Liver Clinic, Hong Kong - Charles Boucher; Erasmus University, The Netherlands
 8:00Plenary Presentation
Clinical Challenges in HCV infection
Mark Sulkowski
Johns Hopkins University, USA
 8:40Eliminating HCV Transmission by Enhancing Care and Treatment Among HCV/HIV Co-infected Individuals in Australia
Joseph Doyle
Monash University, Australia
 9:00Management of HCV in Decompensated liver disease
Michael Manns
Hannover Medical School, Germany
 9:20When are we done? How long do we follow patients with advanced fibrosis or cirrhosis after SVR?
Paul Pockros
Scripps Translational Science Institute, USA
 9:40Panel Discussion
 
10:00Break
 
HEPATITIS C VIRUS - Part 2
Chair: 
Margaret Hellard; Monash University, Australia - Michael Fried; University of North Carolina at Chapel Hill, USA
 10:20Plenary Presentation
DAA Controversies: Do they Cause HBV Reactivation and/or HCC?
Jordan Feld
Toronto General Hospital, Canada
 11:00Pan-genotypic direct-acting antiviral agents: Opportunity to achieve HCV elimination
Tarik Asselah
Hôpital Beaujon, France
 11:20Update on Merck’s HCV Program  
Michael Robertson
Merck, USA
ORAL ABSTRACT SESSION IV 
 11:40

Long term follow-up after Treatment with Ombitasvir/Paritaprevir/ritonavir ± Dasabuvir ± Ribavirin in the AMBER – Real World Experience Study
Robert Flisiak, Medical University of Bialystok, Poland

 11:50

A Next Generation HBV Capsid Inhibitor, AB-506: In Vitro and In Vivo Antiviral Characterization (67)
Nagraj Mani, Arbutus Biopharma Inc., USA

 12:10

Predicting Susceptibility and Resistance for Hepatitis B Virus Capsid Assembly Effectors
Bryan Cox, Emory University, USA

12:20Lunch
 
NASH AND HEPATOCELLULAR CARCINOMA
Chairs: Veronica Miller; Forum for Collaborative HIV Research, USA - Manal El-Sayed; Ain Shams University, Egypt
 15:30Plenary Presentation
NASH Globally: Pathways to Combination Therapy, Biomarkers and Outcomes
Arun Sanyal
Virginia Commonwealth University, USA
 16:10The Re-vival of Bile Acid Based Therapeutics for Children and Adults
Saul Karpen
Emory University, USA
 16:30Evolving Role of Real-World Evidence in NASH and HCC: From Bench to Poolside
Michael Fried
University of North Carolina at Chapel Hill, USA
 

ORAL ABSTRACT SESSION V
Chairs:
Robert Gish, Hepatitis B Foundation, USA - Mario Stevenson, University of Miami, USA

 16:50

Sustained SVR 2 years after HCV treatment with simeprevir, daclatasvir and sofosbuvir in patients with portal hypertension or decompensated liver disease
Eric Lawitz; Texas Liver Institute, USA

 17:00

High Efficacy and Safety of the combination HCV Regimen Grazoprevir and Elbasvir for 8 Weeks in Treatment-Naive, non-severe fibrosis HCV GT1b-Infected Patients: Interim Results of the STREAGER study
Brigitte Chanteranne; CHU Estaing, France

17:10Break
 
ELIMINATION, PREVENTION AND VACCINE Chairs: Frank Chisari, The Scripps Research Institute, USA - Michael Manns, Hannover Medical School, Germany
 17:30Plenary Presentation
Are we Getting Closer to an HCV Vaccine? 
Andrea Cox
Johns Hopkins University, USA
 18:00

Lessons learned towards a Vaccine and Functional Cure for HIV
Mario Stevenson
University of Miami, USA

 
ORAL ABSTRACT SESSION VI
 18:20

Hepatitis B virus splice variants are associated with and predictive of liver cancer (12)
Peter Revill, Victorian Infectious Diseases Reference Laboratory, Australia

 18:30

Seroclearance of HBsAg in Chronic Hepatitis B Virus Patients on Lamivudine, Tenofovir or Entecavir Therapy: A 10 Year Experience.
Suzane K. Ono Nita, University of Saõ Paulo, Brazil

 
18:40Adjourn to Closing Dinner
 

THURSDAY, DECEMBER 7, 2017

ADVANCES IN CLINICAL DEVELOPMENTS:
Chairs: Henry Masur; NIH, USA - Saul Karpen; Emory University, USA
 8:00Plenary Presentation
The Effectiveness of Treatment for Chronic Hepatitis C (and Hepatitis B) in Pediatric Populations

Manal H. El-Sayed
Ain Shams University, Egypt
 8:40Liver Directed Acetyl CoA Carboxylase Inhibitor GS-0976 For NASH
Adrian Ray
Gilead Sciences, USA
 9:00

Aramchol for NASH and beyond: From Scientific Rationale to Clinical Development. 
Carol Brosgart
University of California, San Francisco, USA

 9:20Regulatory Landscape for NASH
Veronica Miller
Forum for Collaborative HIV Research, USA
 9:40Immunotherapies and treatments for HCC
 
10:00Break
 
ORAL ABSTRACT SESSION VII Chairs: Jason Grebely, The University of New South Wales, Australia - Shyamasundaran Kottilil, University of Maryland, USA
 10:30

RNA Interference Screen Identified Farnesoid X Receptor (FXR) as a Host Dependency Factor for HBV Establishment in Primary Human Hepatocytes
Sumantra Ghosh; Gilead Sciences Inc, USA

 10:40

Evidence Supporting Liver Targeting of Tenofovir Exalidex (TXL)
Robert Foster; ContraVir Pharmaceuticals Inc., USA

 10:50

Two Doses of HEPLISAV-B™, a Hepatitis B Vaccine with a TLR9 Adjuvant, Compared with Three Doses of Alum-Adjuvanted ENGERIX-B® in Adults Aged 18 -70 Years
Randall Hyer; Dynavax, USA

 11:00

An Integrated Multidisciplinary Approach for Prediction of Fibrosis Progression and HCC Development in Chronic Hepatitis C Infected Patients Utilizing Genomics, Elastography, Imaging and Circulating Tumor Cells
Emmanuel Thomas; University of Miami, USA

 11:10

Delayed viral suppression during antiviral therapy increases hepatocellular carcinoma in HBeAg-positive chronic hepatitis B
Yoon Jun Kim, Seoul National University Hospital, South Korea

 11:20

Establishment of Functional Control and Normalization of Liver Function in HBeAg Negative Chronic HBV infection Following Combined Therapy with REP 2139 or REP 2165, Tenofovir Disoproxil Fumarate and Pegylated Interferon α-2a.
Andrew Vaillant; Replicor Inc., Canada

 11:30

Validation of a novel Transient Elastography for the Measurement of liver fibrosis
Jing Chen; Humanity and Health Research Centre, Hong Kong

 11:402018 & Beyond: Shifting the conversation
Eugene Schiff
University of Miami, USA
 12:10

Closing Remarks
Raymond F. Schinazi
Emory University, USA